Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRIS: Infliximab vs Cyclophosphamide in Scleritis
NCT03088293Phase 3Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in idiopathic scleritis, sponsored by Hospices Civils de Lyon. Planned start Jun 2020; status: withdrawn.
02
Drugs
infliximab
03
Conditions
idiopathic scleritis
Beyond the preview
Go deeper on NCT03088293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088293.